[Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
Nakao
Kaoru
K
Ando
Akihiro
A
Hirakata
Mikito
M
Ando
Naoki
N
Takeshita
Koichiro
K
Miyamoto
Yohei
Y
Mochizuki
Hidenori
H
D000284:Administration, Oral; D000818:Animals; D002214:Capsules; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009019:Morphinans / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology*; D011957:Receptors, Opioid / Q000819:agonists / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D013141:Spiro Compounds / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D014511:Uremia / Q000150:complications*
D002214:Capsules; D009019:Morphinans; D011957:Receptors, Opioid; D013141:Spiro Compounds; C111212:TRK 820